Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Casi Pharma-Partnered BioInvent's Lead Cancer Program Gets FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation to BioInvent International AB's (OTC:BOVNF) BI-1206, an anti-FcyRllB antibody, for follicular lymphoma (FL) the most common form of Non-Hodgkin lymphoma (NHL).

  • BioInvent is a collaborating partner of CASI Pharmaceuticals Inc (NASDAQ:CASI).
  • BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. 
  • One trial is evaluating the BI-1206 combination with rituximab for Non-Hodgkin lymphoma in patients who have relapsed or are refractory to rituximab. 
  • A second Phase 1/2 trial is investigating BI-1206 in combination with Merck & Co Inc (NYSE:MRK) anti-PD1 therapy Keytruda (pembrolizumab) in solid tumors.
  • Price Action: CASI shares are up 4.21% at $0.72 during the premarket session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.